ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its first Investigational New Drug (IND) application for IMPT-314, a bispecific 'OR-Gate' autologous CAR T-cell therapy aimed at the B-cell antigens CD19 and CD20.
IMPT-314 is to be studied in a Phase one/two clinical trial in subjects with aggressive B-cell lymphoma that includes diffuse large B-cell lymphoma (DLBCL).
The company is planning to commence the Phase one/two clinical trial of IMPT-314 in the first quarter of 2023. During January 2022, the firm raised USD111m in a Series B financing round to build a team of cell therapy, oncology, and immunology specialists, and its clinical manufacturing and quality control laboratory facility in Los Angeles.
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics